- $416.08m
- $421.58m
- $824.50m
US STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics
Myriad Genetics slips after Piper Sandler downgrades to 'underweight'
U.S. RESEARCH ROUNDUP-Health Catalyst, Nektar Therapeutics, TIC Solutions
Myriad Genetics Inc reports results for the quarter ended June 30 - Earnings Summary
Myriad Q2 revenue misses estimates, cuts 2026 revenue outlook
Brief: Myriad Genetics Q2 Revenue USD 190.7 Million Vs. IBES Estimate USD 206 Million
Myriad Genetics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Myriad Genetics Launches Prolaris® + AI
Myriad Genetics Q1 revenue growth misses estimates
Brief: Myriad Genetics Q1 EPS USD -0.36
Brief: Myriad Genetics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Myriad Genetics Q4 adjusted EPS beats estimates
Brief: Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance